Literature DB >> 10686533

Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates.

M Halpern1, A Rentz, M Murray.   

Abstract

PURPOSE: To analyze the direct medical costs associated with epilepsy in the US using a cost-of-illness analysis that incorporates both a patient-based approach and a population-based approach.
METHODS: Patient-based or 'bottom-up' analysis relied on information provided by a panel of experienced epilepsy clinicians to determine the number and type of medical resources used by individuals with epilepsy. Population-based or 'top-down' analysis relied on cost estimates from a nationally representative sample in the 1987 National Medical Expenditure Survey.
RESULTS: The average annual cost per individual in the patient-based analysis was $1,490. The average annual cost per individual in the population-based analysis was $1,510 with average yearly costs per adult of $1,480 and $1,740 per child. New cases of epilepsy are associated with costs of $362 million for the first year of treatment; existing cases of epilepsy are estimated to cost the US nearly $2 billion.
CONCLUSIONS: The results of this study indicate incident cases are more than twice as expensive as prevalent cases, and the need to properly care for epilepsy patients is increasingly important in today's health care environment, where the emphasis is on providing effective treatments while simultaneously lowering the costs.

Entities:  

Mesh:

Year:  2000        PMID: 10686533     DOI: 10.1159/000026243

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  6 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Economic burden of epilepsy among the privately insured in the US.

Authors:  Jasmina I Ivanova; Howard G Birnbaum; Yohanne Kidolezi; Ying Qiu; David Mallett; Sue Caleo
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  Research implications of the Institute of Medicine Report, Epilepsy Across the Spectrum: Promoting Health and Understanding.

Authors:  Dale C Hesdorffer; Vicki Beck; Charles E Begley; Malachy L Bishop; Sandra Cushner-Weinstein; Gregory L Holmes; Patricia O Shafer; Joseph I Sirven; Joan K Austin
Journal:  Epilepsia       Date:  2013-01-07       Impact factor: 5.864

4.  Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy.

Authors:  Lucie Blais; Odile Sheehy; Jean-Marc St-Hilaire; Giles Bernier; Philippe Godfroid; Jacques J LeLorier
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Cost of epilepsy: a systematic review.

Authors:  Adam Strzelczyk; Jens Peter Reese; Richard Dodel; Hajo M Hamer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 6.  Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples.

Authors:  Lan Gao; Hao Hu; Fei-Li Zhao; Shu-Chuen Li
Journal:  PLoS One       Date:  2016-01-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.